Nuno Mendonça

Proceedings of the 3rd IPLeiria’s International Health Congress

Catarina Tomás, Emanuel Oliveira, Denise Carvalho De Sousa et al. · BMC Health Services Research · 2016 · 456 citations · Full text

Public Health, Health Education, Health Promotion +17

Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial

Eugenio Mercuri, Francesco Muntoni, Giovanni Baranello et al. · The Lancet Neurology · 2021 · 256 citations

Medicine, Neurology, Neuroscience +12

Sel1L is indispensable for mammalian endoplasmic reticulum-associated degradation, endoplasmic reticulum homeostasis, and survival

Shengyi Sun, Guojun Shi, Xuemei Han et al. · Proceedings of the National Academy of Sciences · 2014 · 213 citations · Full text

Life Sciences, Cell Biology, Molecular Biology +13

Safety and efficacy of tilavonemab in progressive supranuclear palsy: a phase 2, randomised, placebo-controlled trial

Günter U. Höglinger, Irene Litvan, Nuno Mendonça et al. · The Lancet Neurology · 2021 · 138 citations · Full text

Pharmacy, Neurology, Pharmacotherapy +4

Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies.

Tim West, Yan Hu, Philip B. Verghese et al. · PubMed · 2017 · 136 citations

Life Sciences, Neurology, Neuroscience +14